Health

Allero Therapeutics Expands Management Team with Two Key Hires

( PR4US.com | Press Release | 2020-12-15 11:41:34 )
Ghent, Belgium / Rotterdam, The Netherlands – December 15, 2020

Allero Therapeutics BV, a Belgian-Dutch oromucosal immunotherapy company, today announced the appointment of two key members to its management team.

As of December 1, 2020, Steven Glazer has joined the Company as Chief Medical Officer and Christophe Saillez as Vice President Regulatory Affairs.

Steven Glazer, MD, PhD, brings more than 25 years of senior management experience, including roles as CMO of Monta Bioscience, Idogen, RhoVac and senior R&D positions at Novo Nordisk, Maxygen and BioInvent. In addition, he is a Board Member and Chairman of the Scientific Committee at Immunicum and a Partner at the life science consulting firm Ventac Partners. Steven Glazer has extensive knowledge of drug development, medical and regulatory affairs in pharmaceutical, biopharmaceutical, biotechnology and diagnostic companies in Europe and the United States.

Christophe Saillez is a regulatory and scientific expert with over 20 years experience in global regulatory aspects, CMC, quality assurance and validation, with in-depth knowledge and practice regarding the requirements from regulatory agencies. He held management roles at pharma and biotech companies such as GSK, Actobio Therapeutics, and Janssen Vaccines. He is a biochemical engineer by training.

“We are excited that Steven and Christophe will strengthen our management team and bring significant clinical and regulatory expertise to Allero,” said Emil Pot, CEO of Allero Therapeutics. “Their strong track record will be very beneficial in advancing our proprietary Specific OroMucosal ImmunoTherapy (SOMIT) technology platform, which is leveraging the unique properties of the oral immune system. We believe that we are now very well positioned to further mature our product pipeline in allergic and autoimmune diseases as well as our COVID-19 program in collaboration with Abbreos.”


###

More information:
Email: pot@allerotherapeutics.com
www.allerotherapeutics.com

Media Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info@ akampion com
Tel. +49 40 88 16 59 64 /
Tel. +49 30 23 63 27 68


About Allero Therapeutics

Allero Therapeutics was founded in November 2016 and seed-financed in 2019 by Curie Capital and Swanbridge Capital. Allero Therapeutics is an immunotherapy company building a portfolio of first-in-class programs based on its proprietary Specific OroMucosal ImmunoTherapy (SOMIT) technology platform. The company is developing a pipeline of products in the field of food-related immune disorders such as Celiac Disease and food allergies, which currently affect 10% of the population worldwide - with rising tendency. While there is no cure other than avoidance of particular food ingredients, patients and families are experiencing a significant impact on their quality of life. More info: http://www.allerotherapeutics.com/


Press Information


Published by

Ines-Regina Buth
http://www.akampion.com

Contact Ines-Regina Buth


 

 

 

 

 

 

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact PR4US. We will not be able to assist you. PR4US disclaims the content included in this release.
Preparing for PR: Five Hot Tips for Startups
PR Fundamentals for Startups - MaRS Best Practices
Public Relations 101
Public Relations Strategy in Our World Today!
Introduction to Public Relations
Trends in Communicating
How to Do Marketing/PR on a Budget - CoInvent Startup Summit 2014 New York
Monika Dixon Shares PR Tips